Improving Brain Health Through Genomic Discovery
At the HudsonAlpha Institute for Biotechnology, we use the power of genomics to accelerate the diagnosis and treatment of brain diseases and disorders, from the earliest stages of life through healthy aging.
The human brain is our most complex and defining organ, shaping our thoughts, memories, behaviors, and identity. When disease disrupts its intricate circuitry, the impact reverberates through every part of life.
- 1 in 6 people worldwide are affected by a neurological condition.
- Diagnosis is often slow, leaving families in uncertainty.
- Treatments remain limited for many neurodevelopmental, neuropsychiatric, and neurodegenerative disorders.
From autism to Alzheimer’s disease, the need for faster answers and more effective treatments is urgent.
We believe the key to unlocking better brain health lies within our DNA. HudsonAlpha brings together advanced sequencing, deep analytic expertise, and strong clinical partnerships to:
End the Diagnostic Odyssey
We use whole genome sequencing and other advanced genetic tools to deliver answers in month, not years.
Enabling Early Detection
We identify genetic risk factors before symptoms appear, allowing for earlier diagnosis and preventative treatments.
Advance Precise Therapies
We inform treatments tailored to the unique genetics of each individual.
Our scientists are applying cutting-edge genomic tools across the spectrum of brain science:
Neurodevelopmental Disorders
We’re uncovering the genetic origins of rare conditions like autism or intellectual disability.
Neuropsychiatric Conditions
We are exploring complex factors behind schizophrenia, bipolar disorder, major depressive disorder, and related diseases.
Neurodegenerative Diseases
We are seeking early warning signs, genetic origins, and intervention strategies for Alzheimer’s disease, Parkinson’s disease, ALS, and more.
Our genomics research is driving tangible progress in understanding and combating neurological disorders. Here’s a glimpse into our pioneering work:
How can we detect neurodegenerative diseases earlier?
Diagnosing Neurodegenerative Diseases with a Simple Blood Test
Today, diagnosing diseases like Alzheimer’s often requires expensive and invasive procedures. HudsonAlpha scientists are interrogating the genomes of individuals with neurodegenerative diseases to try to find genetic markers that could be used to diagnose the diseases much earlier. This information can be used to develop simple blood tests that could one day replace these procedures, making early and accurate diagnosis more accessible for everyone. This work could accelerate treatment and improve the quality of life for millions living with neurodegenerative diseases.
Can early lifestyle interventions delay symptom onset in Alzheimer’s disease?
HOPE-AD Pilot Study
The HOPE-AD (Healthy Outcomes through Phenomic Exploration for Alzheimer’s Disease) pilot study is a groundbreaking project designed to uncover the earliest genomic changes associated with Alzheimer’s disease. Led by a multidisciplinary team of HudsonAlpha researchers and other collaborators, the study is focused on individuals who are at a higher genetic risk for developing the disease but have not yet shown symptoms.
By combining advanced genomic sequencing with cognitive testing and other biomarker analysis, the study aims to identify novel genetic factors and biomarkers that could be used for early detection and future prevention. The study is also looking at the effectiveness of early lifestyle interventions for individuals at higher genetic risk.
HudsonAlpha is charting a new course for diagnosing, treating, and preventing brain diseases. Through the lens of genomics, we’re moving toward a future where answers come faster, treatments are more precise, and prevention becomes reality.